Literature DB >> 14987282

Infliximab as a treatment for recalcitrant pyoderma gangrenosum.

M Singh, S M Andrew, J T Lear.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14987282     DOI： 10.1111/j.1365-2230.2004.01470.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN： 0307-6938            Impact factor:   3.470


× No keyword cloud information.
  5 in total

1.  Pyoderma gangrenosum developing during therapy with TNF-alpha antagonists in a patient with rheumatoid arthritis.

Authors:  K Vandevyvere; F P Luyten; P Verschueren; R Lories; S Segaert; R Westhovens
Journal:  Clin Rheumatol       Date:  2007-09-18       Impact factor: 2.980

2.  Development of pyoderma gangrenosum during therapy with infliximab.

Authors:  Natalia Jaimes-López; Verónica Molina; Juan E Arroyave; Luz A Vasquez; Ana C Ruiz; Rodrigo Castaño; Mario H Ruiz
Journal:  J Dermatol Case Rep       Date:  2009-08-24

3.  Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi-systematic review.

Authors:  Hakim Ben Abdallah; Karsten Fogh; Rikke Bech
Journal:  Int Wound J       Date:  2019-01-03       Impact factor: 3.315

4.  Adalimumab therapy for recalcitrant pyoderma gangrenosum.

Authors:  Margaret A Fonder; Deborah L Cummins; Benjamin D Ehst; Grant J Anhalt; Jon H Meyerle
Journal:  J Burns Wounds       Date:  2006-11-20

Review 5.  Extraintestinal Manifestations of Inflammatory Bowel Disease.

Authors:  Stephan R Vavricka; Alain Schoepfer; Michael Scharl; Peter L Lakatos; Alexander Navarini; Gerhard Rogler
Journal:  Inflamm Bowel Dis       Date:  2015-08       Impact factor: 5.325
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.